TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
In the short term, Phentermine features cheap and fast outcomes
What does semaglutide injection pain actually feel like
Kommu, S., and P
Better Attention Span, Focus, and Learning Readiness Many forms of autism sound therapy improve the brains ability to filter background noise